Skip to main content

Navigation group

Type at least 3 characters
707 articles

Articles

Original Research

Published on 21 Feb 2023

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

in Gastrointestinal Cancers: Colorectal Cancer

  • Lisa Salvatore
  • Maria Bensi
  • Raffaella Vivolo
  • Ina Valeria Zurlo
  • Emanuela Dell’Aquila
  • Roberta Grande
  • Annunziato Anghelone
  • Alessandra Emiliani
  • Fabrizio Citarella
  • Maria Alessandra Calegari
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
Frontiers in Oncology
doi 10.3389/fonc.2023.1125013
  • 2,039 views
  • 1 citation